Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4026006 | Ophthalmology | 2015 | 7 Pages |
Abstract
Most lesions with CNV became inactive with 3 injections of ranibizumab, but a small proportion remained active for more than 12 months. Injection frequency and lesion type were the main factors that predicted the time and number of injections required to render lesions inactive.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Mark C. MBBS, PhD, Anna PhD, Richard MSc, Judy M. BSc, PhD, Jennifer J. MBBS, Robyn H. MBBS, PhD, Ian L. MBBS, Alex P. MBBS, FRACS, Rohan W. MBBS, Nigel MBBS, Daniel MD, PhD,